ArticleFrontiers in immunology2026
PM2.5 exacerbates house dust mite-induced allergic rhinitis via STING-mediated nasal epithelial barrier disruption.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The synergistic effect of PM2.5 and house dust mite (HDM) in exacerbating allergic rhinitis (AR) is recognized, but the underlying molecular mechanisms remain unclear. Objective: This study investigated whether PM2.5 aggravates HDM-induced AR and nasal epithelial barrier damage via the STING signaling pathway. Methods: This research combined bioinformatics analysis of a human nasal transcriptome dataset with Results: Bioinformatics analysis linked PM2.5 exposure to TNF/NF-κB signaling. Conclusion: PM2.5 disrupts the nasal epithelial barrier and synergizes with HDM to exacerbate allergic inflammation by activating the STING/NF-κB pathway. This study identifies STING as a potential therapeutic target for environment-aggravated allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.